# Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

> **NCT01142401** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 118 (actual)

## Conditions studied

- Metastatic Breast Carcinoma
- Stage IIIB Breast Cancer AJCC v7
- Stage IIIC Breast Cancer AJCC v7
- Stage IV Breast Cancer AJCC v6 and v7

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Fulvestrant
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01142401
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05-26
- **Primary completion:** 2015-07-30
- **Final completion:** 2021-01-08
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2023-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01142401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01142401, "Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01142401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*